2,228
Views
27
CrossRef citations to date
0
Altmetric
Original Research

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

, , , , , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (11)

Stefan Andreas. (2020) Effects of LAMA/LABA Alone and in Combination on Cardiac Safety. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1931-1933.
Read now
Stefan Andreas, Ulrich Bothner, Alberto de la Hoz, Isabel Kloer, Matthias Trampisch & Peter Alter. (2020) A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1955-1965.
Read now
Stefan Andreas, Ulrich Bothner, Alberto de la Hoz, Isabel Kloer, Matthias Trampisch & Peter Alter. (2020) No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1945-1953.
Read now
Chenxi Li, Wenke Cheng, Jin Guo & Wei Guan. (2019) Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 799-808.
Read now
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola & Josuel Ora. (2019) Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 20:6, pages 737-750.
Read now
Andrea S. Melani. (2018) Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy 19:14, pages 1603-1611.
Read now
Thomas J. Monaco & Nicola A. Hanania. (2017) Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opinion on Emerging Drugs 22:3, pages 285-299.
Read now
Cristoforo Incorvaia, Marcello Montagni, Elena Makri, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2016) Striving for optimal bronchodilation: focus on olodaterol. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 439-444.
Read now
Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Cecilia Calabrese, Rosa Terracciano, Nicola Lombardo & Rosario Maselli. (2015) Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Therapeutics and Clinical Risk Management 11, pages 1563-1572.
Read now
Maria Gabriella Matera, Josuel Ora & Mario Cazzola. (2015) Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol. Therapeutics and Clinical Risk Management 11, pages 1805-1811.
Read now
Wijdan H Ramadan, Wissam K Kabbara, Ghada M El Khoury & Sarah A Al Assir. (2015) Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2347-2356.
Read now

Articles from other publishers (16)

Cristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, Kristina Laugesen, Florian Voss, Jaume Aguado, Ulrich Bothner, Kenneth J. Rothman, Kristina Zint, Daniel Mines & Vera Ehrenstein. (2022) Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists. Pharmacoepidemiology and Drug Safety 31:8, pages 827-839.
Crossref
Gang Xing, Anthony Yiu-Ho Woo, Li Pan, Bin Lin & Mao-Sheng Cheng. (2020) Recent Advances in β 2 -Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure . Journal of Medicinal Chemistry 63:24, pages 15218-15242.
Crossref
Gary T. Ferguson, François Maltais, Jill Karpel, Ulrich Bothner, Isabel Kloer, Matthias Trampisch & Roland Buhl. (2020) Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. npj Primary Care Respiratory Medicine 30:1.
Crossref
Jinchun Wu, Yi Ye, Chenxi Li, Wenqin Zhou & Rong Chang. (2019) Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD. Journal of Cardiovascular Pharmacology 74:3, pages 255-265.
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Gary T. Ferguson, Roland Buhl, Ulrich Bothner, Alberto de la Hoz, Florian Voß, Antonio Anzueto & Peter M.A. Calverley. (2018) Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respiratory Medicine 143, pages 67-73.
Crossref
Stefan Andreas, Ulrich Bothner, Matthias Trampisch, Michaela Haensel, Roland Buhl & Peter Alter. (2018) Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulmonary Pharmacology & Therapeutics 52, pages 1-6.
Crossref
Andrea Koch, Henrik Watz, M. Reza Maleki-Yazdi, Ulrich Bothner, Kay Tetzlaff, Florian Voß & Lorcan McGarvey. (2017) Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. npj Primary Care Respiratory Medicine 27:1.
Crossref
Hyun Woo Lee, Hyung-Jun Kim & Chang-Hoon Lee. (2017) The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis. British Journal of Clinical Pharmacology 83:6, pages 1166-1175.
Crossref
Dave Singh, Giorgia Ciurlia, Annalisa Piccinno, Annamaria Muraro, Maria Bocchi & Mario Scuri. (2017) Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. Pulmonary Pharmacology & Therapeutics 42, pages 43-51.
Crossref
Roland Buhl, Sheldon Magder, Ulrich Bothner, Kay Tetzlaff, Florian Voß, Lazaro Loaiza, Claus F. Vogelmeier & Lorcan McGarvey. (2017) Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine 122, pages 58-66.
Crossref
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini & N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, pages 911-936.
Crossref
Wijdan H. Ramadan, Wissam K. Kabbara & Rosa M. Abilmona. (2016) Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 73:15, pages 1135-1143.
Crossref
Bryony Coupe, Andrew L. Griffiths & Gwyneth A. Davies. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 153 164 .
Kai-Michael Beeh, Craig LaForce, Martina Gahlemann, Arne Wenz, Robert Toorawa & Matjaž Fležar. (2015) Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Respiratory Research 16:1.
Crossref
Emma D. Deeks. (2015) Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs 75:6, pages 665-673.
Crossref